

AD \_\_\_\_\_

GRANT NUMBER DAMD17-96-1-6042

TITLE: Dysregulation of the Stress Response in the Persian Gulf Syndrome

PRINCIPAL INVESTIGATION: Daniel J. Clauw, M.D.

CONTRACTING ORGANIZATION: Georgetown University Medical Center  
Washington, DC 20007

REPORT DATE: June 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19970919 087

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE June 1997	3. REPORT TYPE AND DATES COVERED Annual (6 May 96 - 5 May 97)	
4. TITLE AND SUBTITLE Dysregulation of the Stress Response in the Persian Gulf Syndrome			5. FUNDING NUMBERS DAMD17-96-1-6042	
6. AUTHOR(S) Daniel J. Clauw, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Georgetown University Medical Center Washington, DC 20007			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, MD 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) <p>The overall project objective is to demonstrate that the unexplained symptoms seen in individuals who have returned from the Gulf War are due to the same mechanisms that cause these symptoms in individuals with similar illnesses in the general population (e.g., fibromyalgia, chronic fatigue syndrome, somatoform disorders). The specific aims are to show that: 1) individuals with PGS display centrally mediated disturbances in autonomic tone, and this leads to vasomotor instability and smooth muscle dysmotility, 2) individuals with PGS display diffuse disturbances in nociception (pain threshold) that are partly responsible for many pain-related symptoms seen in this condition (e.g., myalgia, arthralgia, sore throat), and 3) the same neuroendocrine changes seen in fibromyalgia, CFS, and PTSD, characterized by blunting of the hypothalamic-pituitary axes, are seen in PGS, and contribute substantially to the fatigue seen in this condition.</p> <p>PGS patients and appropriate control groups will be admitted to the Clinical Research Center at Georgetown University Medical Center and will undergo testing of autonomic, neuroendocrine, and nociception (pain tolerance) systems. To date, because of difficulty with recruiting patients, we have studied 4 PGS patients and 16 control patients. Recent efforts have been undertaken to enhance recruitment which we feel will be effective in increasing these numbers.</p>				
14. SUBJECT TERMS Gulf War Illness			15. NUMBER OF PAGES 16	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

\_\_\_\_ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

✓ \_\_\_\_ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

\_\_\_\_ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

\_\_\_\_ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

\_\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



5/30/97

PI - Signature

Date

## Table of Contents

Front Page .....	1
Standard Form (SF) 298: REPORT DOCUMENTATION .....	2
Foreword .....	3
Table of Contents .....	4
Introduction .....	5
Body .....	6
Experiemental Methods, Preliminary Data, Conclusions	
References .....	15
Personnel .....	17
Appendices .....	--

## INTRODUCTION

In 1990 and 1991, the U.S. deployed approximately 700,000 troops to the Persian Gulf to liberate Kuwait from Iraqi occupation. Fortunately, there were relatively few combat and non-combat related injuries and diseases during this conflict in comparison with previous military campaigns, and most veterans of this conflict who did develop illness had diagnosable and treatable conditions<sup>1,2</sup>. However, the symptoms of approximately 20% of those with symptoms have not been explained, and this constellation of symptoms occurring in this setting has been termed the Persian Gulf Syndrome (PGS).

We contend that the only unique aspect of the PGS is the location and timing of troop deployment. Similar illnesses have been noted after nearly every major conflict, although these syndromes have had different names and attributions. *More importantly, similar syndromes occur at a high rate in the general population, with the currently preferred terms being fibromyalgia (FM), chronic fatigue syndrome (CFS), somatoform disorder, and multiple chemical sensitivity (MCS).*

We have been extensively involved in the study of these latter illnesses, and there are substantial data suggesting that these syndromes are not discrete entities, but rather fall within a continuum. All of these illnesses are typically both initiated and perpetuated by a variety of physical and emotional stressors, as may have occurred in deployment to the Gulf War and upon return home. The study of these illness has shown that there are a number of objective abnormalities in the human "stress response" which can be identified that are likely responsible for the symptoms seen in these entities.

The purpose of this proposal is to demonstrate that these same objective neurohormonal abnormalities are present in individuals with PGS, and are at least partly responsible for the symptoms noted in these individuals. There are several axes of the stress response that can independently or concurrently function aberrantly in these conditions, including the autonomic nervous system, the hypothalamic-pituitary axes, and descending anti-nociceptive pathways. Specific symptomology results when each of these systems function improperly. In this study we propose to demonstrate that: 1) individuals with PGS display centrally mediated disturbances in autonomic tone, and this leads to vasomotor instability and smooth muscle dysmotility, and symptoms such as irritable bowel syndrome, and migraine headaches, 2) individuals with PGS display diffuse disturbances in nociception (pain threshold) that are partly responsible for many of the pain-related symptoms seen in this condition (e.g., myalgia, arthralgia, sore throat), and 3) the same neuroendocrine changes seen in FM, CFS, and PTSD, characterized by blunting of the hypothalamic-pituitary axes, are seen in PGS, and contribute substantially to the fatigue seen in this condition.

After patients are seen at the Washington, D.C. VAMC for a Comprehensive Clinical Evaluation (CCE), they are asked if they would like to be involved in this research, which is performed at Georgetown University Medical Center. To date, four patients have been studied, as well as 13 FM/CFS patients, and three healthy normal controls (these latter groups are for comparison). There have been no untoward or unexpected adverse events as a result of this testing. We will continue to recruit individuals for this study, with the goal to study 60 PGS patients, 20 controls, and 20 FM/CFS patients.

We feel that the study we have designed will lead to important insights into the symptoms experienced by some Persian Gulf veterans. The demonstration of common underlying pathophysiologic mechanisms in FM, CFS, MCS, and the Persian Gulf veterans will

be tremendously beneficial, in that this should lead both to more effective treatment of these individuals, and perhaps to effective strategies regarding avoidance of this problem in future conflicts.

## **EXPERIMENTAL METHODS**

**Overview.** The current study is being conducted on individuals who have been admitted to the Washington, D.C. VAMC, one of the three Persian Gulf Referral Centers created in August of 1992. This project is a multi disciplinary collaborative effort, involving individuals from Georgetown University Medical Center and the VAMC, as well as consultants from the National Institutes of Health who are recognized as international experts on the effects of stress on the neuroendocrine and autonomic systems. The participants in this study are admitted to the Clinical Research Center (CRC) at Georgetown for two days following their routine admission to the VAMC. Over the course of two days, participants undergo a series of studies that permit the concurrent evaluation of a number of physiologic and biochemical parameters.

The physiologic studies performed measure both the qualitative and quantitative aspects of a number of symptoms, and include specialized testing of peripheral and visceral nociception, and smooth muscle motility. We also evaluate multiple indices of autonomic function, including neurohormone levels at baseline and after standardized stressors, and cerebral spinal fluid (CSF) levels of nociceptive neurotransmitters.

We are employing several control groups: 1) "healthy normals", 2) PGS patients without a symptom or feature being studied, and 3) individuals with CFS and FM. The purpose of the healthy normal control group is to show that the PGS patients differ from age and gender matched controls; this is the most common type of control group employed for this type of study. However, merely identifying that the group mean of a variable in PGS patients differs from that in a control group will tell us very little about PGS. For this reason, for each hypothesis we study two other control groups. The first is a cohort of PGS patients without the symptoms or feature being studied. We know from experience that there is tremendous heterogeneity in the clinical and pathophysiologic expression of disorders such as PGS, such that within the group of PGS patients, some patients will and others will not exhibit a certain feature (e.g. smooth muscle dysmotility). In this instance, for example, we would predict from our pilot data that approximately half of the 60 PGS patients we study will display objective evidence of smooth muscle dysmotility on manometric study. The hypothesis being tested with this variable is that the smooth muscle dysmotility is due to centrally mediated autonomic dysfunction. Thus, we will divide the entire group of patients with PGS into those with and without smooth muscle dysmotility, and demonstrate that the group with dysmotility exhibits autonomic dysfunction, and those without dysmotility do not display autonomic dysfunction. The group of PGS patients without dysmotility should only differ from those with dysmotility with regards to that single variable, and should thus be better matched than alternative control groups.

Finally, we will compare the results of the pathophysiologic studies with the same tests performed concurrently in FM and CFS, to demonstrate that there are no differences between the PGS patients and the FM/CFS groups. We concurrently have several grants to examine autonomic and nociceptive function in these cohorts of patients, so these comparisons can be performed without the need for significant additional funding.

**Subject recruitment.** We will evaluate 60 consecutive Persian Gulf veterans who are referred to

the Washington VAMC for a CCE, and 20 age- and gender-matched healthy controls. Because individuals with PGS without certain symptoms will also be serving as controls (see above), we chose to study a larger number of patients than controls.

Studying individuals who are being admitted to the VAMC for a CCE has several advantages over the use of alternative sources of PGS patients: 1) individuals in our study will be well screened for alternative causes of symptoms, and will be precluded from participation, and 2) these individuals will have extensive baseline testing performed as part of the CCE which will be available for analysis.

a) *Definition of PGS.* Because there is no widely-accepted definition of PGS, this is a difficult issue. We sought to develop a definition of PGS that would truly select individuals who served in the Gulf War who have a significant unexplained illness. Thus, the definition we have employed for purposes of this study is that: 1) unexplained symptoms developed within 6 months of participation in the Gulf War, and continue to be active, and 2) those symptoms include 3 or more of the following: myalgia, arthralgia, headache, fatigue severe enough to limit activities, cognitive dysfunction, sensitivity to multiple environmental substances, pulmonary symptoms, and GI symptoms. We recognize that not all will agree with this definition, and if a consensus definition is developed before we begin this study, that definition will be used instead. However, we feel that this definition encompasses most of the symptoms which have been reported by Persian Gulf participants with unexplained symptoms, yet the definition is not too restrictive to identify only individuals who would meet the established criteria for FM, CFS, MCS, etc.

b) *Inclusion and exclusion criteria.* Entry and exclusion criteria, other than meeting the above noted PGS criteria, include: 1) ages 18 to 60, and 2) subjects must not consume any antidepressant, tricyclic compound, benzodiazepine, anti-inflammatory, or antipsychotic medication for two weeks prior to study (these drugs interfere with testing being performed).

Control recruitment. 20 healthy normal individuals who are matched for age and gender to represent the study population will be randomly selected. These individuals will be compensated for participation, and the primary source of controls will be employees and students at Georgetown University Medical Center. As noted, these individuals will be matched for age and gender. Once again, we feel that the selection of this control group is less critical because we are employing several control groups in this study.

Methods. Eligible patients and controls will give informed consent and be scheduled for admission to the Georgetown University Medical Center CRC. The testing throughout the day will occur in the CRC, except for the gastroenterology portion. The schedule of testing is listed below, and the sequence will be identical for subjects and controls. This testing sequence is similar to that utilized in our pilot studies, so we are comfortable that patients will be able to tolerate testing without difficulty, and tests that are sensitive to fatigue (e.g. cognitive testing) are scheduled in the morning. Methods for each test, and justification where appropriate, are described in detail below.

	Day One	Day Two
MORNING	Serum and blood collection (8AM) [Begin 24-hour urine collection and Holter monitoring] Tender point examination Tilt table testing COGSCREEN	Serum and blood collection (8AM) [Remove Holter monitor and complete 24 hour urine collection] Dolorimeter exam Lumbar puncture Gastroenterology evaluation
AFTERNOON	Structured Clinical Interview (SCID) Serum collection (4PM)	
EVENING	Complete self-report questionnaires	

**Serum collection.** Serum and plasma are collected utilizing standard venipuncture techniques. As noted, blood is drawn at standardized times throughout the study to eliminate discrepancies due to diurnal variation. Samples are placed on ice immediately and kept dark until they can be centrifuged. Sera will be distributed into several aliquots and stored at -70°C at two different locations.

**Dolorimeter examination.** A dolorimeter is a simple mechanical pressure gauge designed to quantify pain threshold and tolerance. For this examination, the pressure (in kg) necessary to produce discomfort (pain threshold) and unbearable pain (pain tolerance) at 18 designated tender points and 4 control points is recorded. This testing will produce five variables for each subject: tender point threshold and tolerance, control point threshold and tolerance, and tender point count.

Since there is such a high correlation between the first four values ( $r > .85$  in our pilot studies), we will utilize the tender point threshold as the measure of peripheral pain for primary data analysis. This test had the least variance and best ability to separate FM patients from controls in our pilot data.

**Autonomic function. Overview.** The assessment of autonomic function in humans is complex. There are no tests of either sympathetic or parasympathetic function that are all-encompassing. In ordinary situations, there are a number factors controlling of visceral motor function, including central autonomic input (which we are measuring), nonadrenergic noncholinergic (NANC) nerves, local reflex loops, and local neurochemical effects. Because symptoms suggestive of smooth muscle dysmotility occur in several organs in CFS, we hypothesize that *aberrant centrally mediated autonomic input* is the predominant stimulus for the abnormal motility. Although the tests we have chosen will assess total autonomic tone, we will focus on those tests which measure the central component of autonomic tone.

In addition to testing basal central autonomic tone, the proposed studies will test the response of the autonomic nervous system to standardized physiologic stressors (pain from dolorimeter exam, mental concentration during cognitive testing, tilt table testing). We are



testing neuroendocrine function and smooth muscle motility in the same manner. We feel that this is a significant strength of the study we have proposed, because all clinical and laboratory evidence in CFS suggests to an inability to respond normally to physiologic stressors. We propose that PGS patients will exhibit similar aberrant stress responses. The stressors we have chosen are likely to accentuate the anomalies in the stress response, especially when compared to some techniques such as response to valsalva or deep breathing (autonomic testing), or response to CRH (neuroendocrine testing).

*Holter monitoring.* Heart rate variability monitoring has been demonstrated to be a very accurate means of assessing both the sympathetic and parasympathetic components of autonomic tone [3]. This can be performed by temporal or spectral analysis over an entire 24 hour period, or over short intervals of time, to determine how the autonomic nervous system functions in response to specific stimuli. Individuals with low efferent parasympathetic tone will display an elevated resting heart rate, and heart rate variation with breathing. Sympathetic tone can likewise be assessed with this technique, with tilt table testing as a useful adjunct in this regard. An especially useful feature of Holter monitoring to assess autonomic tone is that it affords a functional assessment of autonomic function over an extended period of time that includes provocative maneuvers and stressful events (tilt table testing as well as visceral and peripheral nociceptive testing). This is especially important since in the chronic phase of these disorders, we hypothesize that individuals may be particularly impaired in their ability to respond to these stressors.

Patients wear a standard ambulatory ECG recorder for the initial 24-hour period of the study. Data will be analyzed using a dedicated Marquette series 8000 analyzer with specialized software for Heart Rate Variability. A diary will be kept so that we can later analyze how the subjects respond to each of these stimuli. In addition, this Holter monitor allows the "marking" of "events" (e.g. the onset of tilt table testing, cognitive testing, lumbar puncture) on the tape, so that the autonomic responses to these specific stressors can be analyzed.

*Tilt table testing.* Tilt table testing allows a standardized method of assessing primarily the sympathetic component to central autonomic tone. With tilting in normals, the systolic blood pressure may fall as much as 15 mm Hg, whereas the diastolic may drop up to 5 mmHg. Any fall of blood pressure greater than this is considered abnormal. There are few good tests to differentiate afferent from efferent sympathetic dysfunction; perhaps the best is vasopressin release in response to tilt table testing, which is abnormal in aberrant afferent function, and will be utilized in this study <sup>4</sup>.

Individuals are supine on a tilt table with foot support and secured in position. The subject rests in this position for at least 10 minutes. Blood pressure and heart rate are recorded using an automatic blood pressure recorder. After 10 minutes, a baseline sample for plasma vasopressin is drawn via the previously placed antecubital catheter into a EDTA tube, and the patient is tilted to a 70 degree head-up position. Blood pressure and heart rate will be recorded every minute, and blood samples are drawn every five minutes through minute-15. As with earlier samples, the blood will be kept on ice and in the dark until centrifugation. All samples are frozen at -70°C for later batch analysis. Vasopressin and Neuropeptide Y will be determined using a commercially available I<sup>125</sup> kits. Utilizing this protocol, normals will display an approximately threefold increase in vasopressin with tilting. Those individuals with afferent sympathetic dysfunction display no change in their vasopressin with tilt, whereas those with sympathetic dysfunction with an intact afferent axis (thus efferent dysfunction) display a 30-fold

increase in vasopressin levels <sup>4</sup>.

Gastrointestinal evaluation. For evaluation of esophageal smooth muscle tone, and esophageal nociception, we follow the standard protocols for motility studies and Bernstein tests. The results obtained include baseline manometric data (normal or abnormal, based on defined criteria), as well as the results of three provocative tests (chest pain with edrophonium, dysmotility with edrophonium, and modified Bernstein test). Also, the diameter of an esophageal balloon required to elicit pain is recorded.

The data which will be utilized in primary data analysis are: 1) the presence or absence of baseline dysmotility, which will be compared to autonomic tone, and will test *Hypothesis c*, and 2) the diameter of balloon causing nociception, which measures visceral nociception, and will be used to test *Hypothesis a*.

Neuroendocrine studies. Samples are collected in a uniform manner, so that we can retain the ability to secondarily analyze the neurohormonal response in a more uniform manner to give us an assessment of the integrity of this system. At this juncture in our understanding of these disorders, we recognize the perturbations in the neuroendocrine system, but are not certain of the physiologic consequences, or whether these are primary or secondary effects. Therefore, we do not feel that further hormonal provocative testing is required. In fact, although provocative tests with "releasing" hormones tests are commonly utilized because conditions and results can be standardized, they give a somewhat artificial understanding of neuroendocrine functional status. We feel that a more relevant physiologic test of the neuroendocrine system in a disorder such as CFS is to determine how subjects respond to standardized physical and emotional, rather than hormonal, stressors. Therefore, we have designed this study to look at the level of hormones at given points in time (8AM and 4PM), under standardized testing conditions (including physical [lumbar puncture, gastrointestinal] and emotional [cognitive testing] stressors), to determine both the basal level of these hormones and the capacity to change levels in response to a physiologic stimulus. We will have collected this same data taken under identical conditions on both PGS patients and controls, at both baseline and after stressors, which will allow us to assess further the differences between the neuroendocrine function within the group of patients, as well as between PGS patients and controls.

Structured Clinical Interview (SCID) and psychiatric evaluation. An extensive psychiatric evaluation is being performed as part of this study because psychiatric co-morbidity is high in all of the disorders related to PGS, including FM, CFS, and MCS. As noted previously, psychiatric variables will be used in the secondary analysis of data to determine if these are important co-factors in symptom expression or in the outcomes of physiologic studies. The primary purpose of this portion of the evaluation is to 1) determine the presence of *present* psychiatric disorders, 2) determine the presence of *pre-existing* psychiatric diagnoses, and the effect on the expression of symptoms, and 3) measure the intensity of psychiatric variables such as depression, anxiety, somatic amplification, and use these measures as co-variables to dependent variables such as nociception, autonomic function, and neuroendocrine function.

The psychiatric evaluation utilizes the following instruments, which have all been extensively validated, and have been utilized in research in FM, CFS, and allied conditions:

- 1) A Structured Clinical Interview for DSM-III-R (SCID) <sup>5</sup>. The structured clinical

interview is used to generate current and lifetime psychiatric disorders such as mood disorders, anxiety disorders, and somatoform disorders. A PTSD module is included as well. The SCID is widely used as the "gold standard" for psychiatric diagnosis in the research setting. The interview is conducted by either Dr. Epstein or a subordinate who has been appropriately trained. Particular attention will be paid to the timing of all psychiatric symptoms, including somatization symptoms, as they correspond to service in the Persian Gulf War.

2) Beck Depression Inventory (BDI)<sup>6</sup>. The BDI is a 21-item measure of the severity of current depressive symptoms, including both neurovegetative and cognitive symptoms of depression.

4) The RAND 36 item health survey<sup>7</sup>. This survey is a self-report measure of functional health status that has been widely utilized. Eight domains will be assessed: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, social functioning, energy/fatigue, and general health perception.

5) NEO PI-R<sup>8</sup>. The NEO is a self-report inventory for the assessment of personality traits based on a five factor model of personality.

6) Barsky Amplification Scale<sup>9</sup>. This ten item scale measures somatosensory amplification, the tendency to experience somatic sensations as unusually intense or disturbing.

Self-report questionnaires. Subjects complete a packet of self-report questionnaires designed to evaluate assorted symptoms and perceptions regarding pain and fatigue.

Urine collection. Urine is collected for during the initial 24-hour period of the study, for archival storage in potential determination of neurohormonal levels, as noted above.

Computerized Cognitive Testing. This battery takes approximately 50 minutes to administer, and has been validated as a sensitive measure of cognition, especially in the areas of interest (attention and short-term memory)<sup>10</sup>. *In this study, we are using computerized cognitive testing as a psychological stressor, not to test any hypotheses regarding cognition in CFS. There are considerable animal data suggesting that the physiologic response to physical and emotional stressors may be quite different, so we have incorporated both into our study design.* These data can be secondarily analyzed to determine the factors which predict cognitive impairment, but this is not the primary intent of the study.

Lumbar puncture. A lumbar puncture will not routinely be performed on all individuals in the study, but a significant number (about 75%) have this study performed as part of their Comprehensive Clinical Evaluation. Thus, in collaboration with our colleagues at the VAMC, we will assure that the testing is performed in a uniform manner so that the CSF can be analyzed for differences in neuromodulator concentrations in the PGS group and controls.

Because there are regional differences in the concentrations of all neuromodulatory substances, CSF analysis is not the optimal manner to study the functional concentrations of neurotransmitter substances. Nonetheless, in human studies these assays can still provide useful information, and are clinically accessible. This is because CSF studies can give insight into the milieu that spinal neurons are operating within. Although CSF obtained from a lumbar puncture typically displays different absolute concentrations of biochemicals than seen in ventricular fluid,

where this has been studied the relative concentrations are typically the same <sup>11</sup>.

Studies have demonstrated that individuals with fibromyalgia have approximately threefold higher concentrations of SP in cerebrospinal fluid than normal controls <sup>12,13</sup>. There are existing data to suggest that the CSF in FM patients is characterized by high substance P and low serotonin and norepinephrine metabolites, and that individuals with migraine headache are characterized by high concentrations of excitatory amino acids, as well as evidence of low serotonin <sup>11,12,14</sup>. We feel that it is imperative to concurrently measure the neuromodulators that control pain and are likely to be abnormal in CFS, to give an accurate picture of the cause of aberrant nociception. Similarly elevated values have been noted for CSF levels of NGF, which is another pro-nociceptive peptide. There is a fourfold elevation of this compound in fibromyalgia patients, and again patients display very little overlap with controls <sup>15</sup>. This neurotrophin is released during growth or damage to nerves, and perhaps in other pathologic circumstances, and causes hyperalgesia and allodynia when given to animals or humans <sup>16</sup>.

These high levels of SP and NGF in the CSF of patients with fibromyalgia could conceivably be causing the pain these individuals are experiencing, or may be the result of the pain. However, Russell has shown that in fibromyalgia patients, levels of CSF SP remain very stable over several months, despite wide fluctuations in the level of pain <sup>17</sup>. Furthermore, SP levels do not change in response to an acute painful stimulus <sup>17</sup>. Also, the same magnitude in elevation of CSF SP is found in fibromyalgia patients with and without psychiatric comorbidities <sup>18</sup>. These aggregate data, as well as animal studies, suggest that SP and NGF levels in the CSF are not influenced by acute pain or by mood. Instead, these data suggest that there is an abnormality in neural function in individuals with this disorder, which is independent of psychological status.

There have been many other physiologic abnormalities identified in individuals with fibromyalgia, any of which might also contribute to the widespread pain that these individuals experience (as well as some other prominent symptoms seen in this disorder, such as fatigue, weakness, insomnia, etc.). Examples of other abnormalities include changes in autonomic nervous system function, disturbances in visceral nociception, and a variety of neuroendocrine abnormalities <sup>19</sup>.

We will utilize CSF analysis to measure the concurrent levels of five substances (or metabolites) in the spinal fluid: Substance P, serotonin, glutamate, norepinephrine, and CRH. These substances were chosen for one of two reasons: 1) because existing data suggest abnormal concentrations in FM (serotonin, Substance P, norepinephrine) or 2) because the substance is known to play a key role in nociception, and has not yet been studied in this condition (glutamate and CRH). Several substances which are known to affect pain tolerance are not being studied because previous investigations have shown that the abnormality seen in FM would not increase nociception. For example, endogenous opiates have been shown to be *high* in both FM and depression, and thus are unlikely to contribute to the increased nociception seen in these entities <sup>20,21</sup>. In addition, two of the substances chosen are not present in detectable concentrations in the CSF (norepinephrine, serotonin), so the direct metabolites will be measured (3-methoxy-4-hydroxyphenethylene [MHPG] and 5-hydroxyindole acetic acid [5-HIAA] respectively).

The two neuromodulators being examined for the first time in this spectrum of diseases are glutamate and CRH. Glutamate is the principal excitatory amino acid (EAA) in humans. EAAs act at a number of receptors, but the most relevant for nociception appears to be the NMDA

receptor, as previously noted. There have been a number of studies suggesting that various neurological disorders are characterized by aberrant levels of excitatory amino acids, with the most work done with glutamate<sup>22,23</sup>. Some have been critical of the glutamate data because of inconsistencies between studies, but the reason for this appears to have been elucidated in a recent study by Ferrarese et. al.<sup>24</sup>. These investigators demonstrated that glutamate is unstable under a number of different handling conditions (including storage at -70°C) unless samples are first acidified (to inactivate the enzymes responsible for degradation) and then neutralized. We will utilize this protocol, and along these same lines, will add neuropeptidase inhibitors to a tube of CSF to make certain that Substance P levels are stable. CRH is being measured because, like the excitatory amino acids, this exerts a pro-nociceptive effect. Concentrations of CRH are likewise detectable in CSF<sup>25,26</sup>. Utilizing these data, we will develop an equation to predict peripheral and visceral nociception. Yunus utilized a similar statistical method that integrated only peripheral (not CSF) levels of amino acids and catecholamines in this equation, and found that the resultant formula had an accuracy of 82% in distinguishing FM patients from controls<sup>27</sup>. There are several neuromodulators which we have not proposed to study (e.g. GABA and metabolites, endogenous opiates) which can easily be assayed on archival samples, since we are taking great care in handling specimens to prevent degradation.

The lumbar puncture will be performed at the same time in all subjects using standard clinical techniques. Because the technique itself could conceivably cause changes in neurotransmitter or hormone levels because of the inherent pain, we will sequentially label 1 cc aliquots of CSF, and the same tube number will always be used for the same assay in all patients and controls. As with the serum, samples are stored at -70°C and processed in batches. These and all other assays are performed by the technicians who are blinded to subject conditions. 5-HIAA and MHPG will be performed in Dr. Russell's lab by HPLC with electrochemical detection, as previously described<sup>11</sup>. CRH assays will be performed by RIA via the collaboration with Dr. Chrousos, at Hazelton Labs. Glutamate will be measured by Dr. Russell using HPLC. Substance P is measured using commercial RIA kits in Dr. Clauw's laboratory.

**Sample Size Calculations.** A sample size of 60 CFS patients and 20 healthy normal controls was chosen for this study, and is more than adequate to test the primary hypotheses. The patient group has been chosen to be larger than the "healthy control" group because to test each of the hypotheses, the patient group will be divided into two groups: one with and the other without the symptom or objective finding (pain, dysmotility, etc.) being studied. For testing differences among means we are seeking to identify a difference of one or more standard deviations between groups as statistically significant ( $p=.05$ ). Differences of less than one standard deviation in this context are unlikely to be biologically meaningful. The standard computation shows 1) that a sample size of 60 patients and 20 controls gives a power of greater than 90% to detect these differences, even after allowing for moderate adjustments to the p value for multiple hypotheses, and 2) that the projected sample sizes enhanced to include extra cases will produce this same power even when the comparisons are done between two subgroups of the CFS patients.

**Data analysis.** All data analysis will be performed with the assistance of Dr. Chase, in his role as the Biostatistical Consultant for this project.

**Preliminary Data:**

We will send our biological samples for batch analysis once we recruit more subjects. Regarding the data from other aspects (e.g. tilt table, esophageal motility studies, holter monitoring, etc.), again, the small sample size makes it difficult to report and interpret data. Recent efforts have been undertaken to enhance recruitment, such as more frequent communication with the VAMC, and attempts have been made to accommodate the PGS patients during their off-days of the CCE. We feel these efforts, in addition to word-of-mouth reports by our past subjects, we will be effective in increasing our numbers in the coming year.

**Conclusions:**

The small sample size precludes any widespread conclusion thus far.

## References

1. Institute of Medicine: Health consequences of service during the Persian Gulf War: Recommendations for research and information systems. 1996; (Abstract)
2. Haley R, Kurt T, Hom J: Is there a gulf war syndrome? searching for syndromes by factor analysis of symptoms. JAMA 1997; 277: 215-222.
3. Ochs RL, Stein TW, Jr., Peebles CL, Gittes RF, Tan EM: Autoantibodies in interstitial cystitis. J Urol 1994 Mar 1994; 151: 587-592.
4. Kaufmann H, Oribe E, Miller M, Knott P, Wiltshire-Clement M, Yahr MD: Hypotension-induced vasopressin release distinguishes between pure autonomic failure and multiple system atrophy with autonomic failure. Neurology 1992; 42: 590-593.
5. Spitzer RL, Williams JBW, Gibbon M, First MB: Structured clinical interview for DSM-III-R. American Psychiatric Press 1990; (Abstract)
6. Beck AT, Rush AJ, Shaw BFe: Cognitive therapy of depression. Guilford 1979; (Abstract)
7. Ware JE, Serbourne CD: The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care 1992; 30: 473-483.
8. Costa PT, McCrae: A six-year longitudinal study of self-reports and spouse ratings on the NEO personality inventory. J Person Soc Psych 1988; 54: 853-863.(Abstract)
9. Barsky AJ, Barnett MC, Cleary PD: Hypochondriasis and panic disorder. Boundary and overlap. Arch Gen Psychiatry 1994; 51: 918-925.
10. Kane R, Kay GG: Computerized assessment in neuropsychology: a review of tests and test batteries. Neuropsychology Review 1992; 3: 1-117.
11. Russell IJ, Vaeroy H, Javors M, Nyberg F: Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis [see comments]. Arthritis Rheum 1992 May 1993; 35: 550-556.
12. Russell IJ, Orr MD, Littman B, et al: Elevated cerebrospinal fluid levels of Substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994; 37(11): 1593-1601.(Abstract)
13. Vaeroy H, Helle R, Forre O, Kass E, Terenius L: Elevated CSF levels of Substance P and high incidence of Raynaud's phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988; 32: 21-26.
14. Ferrari MD, Odink J, Bos KD: Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 1990; 40: 1582-1586.

15. Giovengo SL, Russell IJ, Larson AA: Increased concentration of Nerve Growth Factor (NGF) in cerebrospinal fluid of patients with fibromyalgia. *J Musculoskel Pain* 1995; 3: (Abstract)
16. Nachemson A: Research methods in occupational low-back pain. *Spine* 1991; 16: 666-667.
17. Russell IJ, Vipraio G, Fletcher EM, Lopez YM, Orr MD, Michalek JE: Characteristics of spinal fluid Substance P and calcitonin related gene peptide in fibromyalgia syndrome. *Arthritis Rheum* 1996; 39: 1485(Abstract)
18. Bradley LA, Alberts KR, Alarcon GS, et al: Abnormal brain regional cerebral blood flow and cerebrospinal fluid levels of Substance P in patients and non-patients with fibromyalgia. *Arthritis Rheum* 1996; 39: 1109(Abstract)
19. Clauw DJ: The pathogenesis of chronic pain and fatigue syndromes, with special reference to fibromyalgia. *Medical hypotheses* 1995; 44: 369-378.(Abstract)
20. Vaerly H, Nyberg F, Terenius L: No evidence for endorphin deficiency in fibromyalgia following investigation of cerebrospinal fluid (CSF) dynorphin A and Met-enkephalin-Arg6-Phe7. *Pain* 1991 Aug 1993; 46: 139-143.
21. Genazzani A, Petraglia F, Sinforiani E, Brambilla F, Facchinetti F, Nappi G: Dysregulation of plasma pro-opiomelanocortin-related peptides in neurotic depression. *Acta Endocr* 1986; 112: 1-6.
22. Lakke JPWF, Teelken AW: Amino acid abnormalities in cerebrospinal fluid of patients with parkinsonism and extrapyramidal disorders. *Neurology* 1976; 26: 489-493.
23. Rothstein JD, Tsai G, Kuncel RW, et.al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. *Ann Neurol* 1990; 28: 18-25.
24. Ferrarese C, Pecora N, Frigo M, Appolonio I, Frattola L: Assessment of reliability and biological significance of glutamate levels in cerebrospinal fluid. *Ann Neurol* 1993; 33: 316-319.
25. Noel M, Nemeroff CB: The role of non-opioid peptides in pain. *Pain Headache* 1987; 9: 194-212.
26. Pert A: Cholinergic and catecholaminergic modulation of nociceptive reactions. *Pain Headache* 1987; 9: 1-63.
27. Yunus MB, Aldaq JC, Dailey JW, Jobe PC: Interrelationships of biochemical parameters in classification of fibromyalgia patients and normal controls. *Arthritis Rheum* 1992; 35(9S): A265